Transcode Therapeutics Inc (RNAZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) has a cash flow conversion efficiency ratio of -0.788x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.14 Million) by net assets ($10.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Transcode Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Transcode Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Transcode Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Transcode Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Transcode Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LUPAKA GOLD CORP.
F:LQPA
|
0.173x |
|
Fabric.AI, Inc.
NASDAQ:FABC
|
-0.170x |
|
Dermata Therapeutics Inc
NASDAQ:DRMA
|
-0.214x |
|
TENET FINTECH GROUP INC.
F:P0T
|
-17.433x |
|
Akash Infra-Projects Limited
NSE:AKASH
|
0.021x |
|
Halfords Group PLC
LSE:HFD
|
0.193x |
|
IMMO BLOCKCHAIN EO 1
F:QT5
|
N/A |
|
Hapbee Technologies Inc
V:HAPB
|
0.329x |
Annual Cash Flow Conversion Efficiency for Transcode Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Transcode Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Transcode Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.34 Million | $-19.52 Million | -1.888x | -128.58% |
| 2024-12-31 | $-2.02 Million | $-13.34 Million | 6.606x | +159.97% |
| 2023-12-31 | $1.64 Million | $-18.07 Million | -11.016x | -126.48% |
| 2022-12-31 | $3.24 Million | $-15.76 Million | -4.864x | -1784.33% |
| 2021-12-31 | $20.40 Million | $-5.27 Million | -0.258x | -278.46% |
| 2020-12-31 | $-3.41 Million | $-492.97K | 0.145x | -68.78% |
| 2019-12-31 | $-1.10 Million | $-508.51K | 0.463x | -22.05% |
| 2018-12-31 | $-503.97K | $-299.57K | 0.594x | -- |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its… Read more